AI-assisted clinical decision-support platform identifies medication risks, hypothetical deprescribing scenarios, and clinical documentation and outreach.
CLEVELAND, OH, UNITED STATES, September 8, 2026 /EINPresswire.com/ — Resolve Medical, LLC today announced the availability of IntractMD™ Deprescribing Intelligence, an AI-assisted clinical decision-support capability designed to help pharmacists, medication therapy management (MTM) programs, and care teams identify potential medication risks and evaluate potential deprescribing scenarios.
The capability is designed to complement, rather than replace, existing pharmacist and clinical medication-management workflows, particularly for polypharmacy patients with complex medication regimens. IntractMD provides information and scenarios for clinical review and does not recommend that a medication be discontinued or that a patient’s current regimen be modified.
The announcement comes as medication management and medication safety continue to receive increased attention across Medicare and other healthcare organizations. Activities associated with comprehensive medication management—including care-plan development and revision, patient communication, symptom monitoring, and coordination among members of the care team—can be important components of broader patient-care and care-management workflows when applicable program and service requirements are met.
“Deprescribing is becoming an increasingly important component of medication safety and efforts to reduce medication-related risk,” said Tom Lash, Founder & CEO of Resolve Medical. “For pharmacists and care teams, identifying where to begin and documenting the clinical reasoning can be time-consuming. Existing tools often focus on identifying individual medication risks. Our patent-pending Deprescribing Intelligence capability models hypothetical medication-removal scenarios and immediately provides a ranked list for clinical review, including projected changes in composite polypharmacy risk and supporting clinical criteria and evidence. This provides a structured way to assess and document potential deprescribing strategies.”
FROM MEDICATION LIST TO DEPRESCRIBING SCENARIOS
IntractMD’s patent-pending Deprescribing Intelligence capability uses an N+1 counterfactual approach to model hypothetical medication-removal scenarios. The platform evaluates medications one at a time, recalculating the Composite Polypharmacy Risk Score (CPRS) across eight clinical dimensions for each hypothetical scenario, leveraging published deprescribing criteria from AGS Beers, STOPP/START, and CMS Star Ratings measures.
The resulting scenarios can be ranked to help pharmacists and care teams identify medications that may warrant further clinical review and evaluate the potential change in the patient’s overall polypharmacy risk profile.
The platform can link potential deprescribing candidates to recognized clinical criteria and guidance and provide a before-and-after CPRS comparison, structured clinical briefing, supporting evidence citations, and PDF export to assist with clinical documentation and communication.
These capabilities are designed to support—not replace—the clinical judgment of pharmacists, prescribers, and other qualified healthcare professionals.
IntractMD is designed to help move care teams from medication-risk identification to structured clinical review, patient communication, and follow-up. Its Clinical MTM Workflow can generate patient outreach communications, including email, SMS, and call scripts in English or Spanish, supporting communication with patients and coordination with the prescribing team.
WHY IT MATTERS NOW
Medication safety and polypharmacy remain important areas of focus for Medicare organizations, health plans, clinical pharmacy programs, and care-management teams. CMS quality measures addressing medication safety, including polypharmacy and potentially inappropriate medication combinations, are increasing attention on systematic approaches to identifying and addressing medication-related risk.
For health plans and clinical pharmacy organizations, the combination of medication-safety quality initiatives and increased attention to comprehensive medication management creates an opportunity to make medication review and deprescribing workflows more systematic.
IntractMD is designed to complement existing drug-interaction, medication-review, and pharmacist clinical-review processes rather than replace them.
60-DAY PILOT AVAILABLE
Resolve Medical is offering qualified organizations a no-cost 60-day evaluation of IntractMD. The platform includes a patient-facing drug Interaction Checker, a Proactive Supplement & Food Screening Engine, Clinical MTM Workflow, and Deprescribing Intelligence capability. No EHR integration is required to begin a pilot. Details are available at: www.resolve.med
The program is intended for health plans, pharmacy organizations, medication therapy management programs, and hospital or health-system clinical pharmacy teams interested in evaluating new approaches to medication-risk identification and clinical workflow support.
ABOUT RESOLVE MEDICAL, LLC
Resolve Medical, LLC is a Cleveland, Ohio-based healthcare technology company developing and launching IntractMD™, an AI-assisted medication-risk and polypharmacy clinical decision-support platform for patients, health plans, pharmacy organizations, and clinical pharmacists.
IntractMD is designed to support the evaluation of prescription medications, supplements, over-the-counter products, and other medication-related factors within its clinical decision-support architecture. The platform incorporates medication and health-information resources, including applicable data from FDA, NLM RxNorm, and MedlinePlus, and applies AI-assisted technology to support medication-risk analysis and clinical workflows.
Resolve Medical is committed to making medication-safety intelligence more accessible to patients, caregivers, pharmacists, and care teams. IntractMD™ is a clinical decision-support tool and is not a substitute for professional medical advice or independent clinical judgment.
Tom Lash
Resolve Medical, LLC
+1 216-509-0672
info@resolve.med
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
